Therapies Targeting Cancer Stem Cell Proliferation

Phost'in Therapeutics is pioneering the development of First-In-Class Glycocalyx Modifiers, specifically targeting aberrant N-glycosylation mechanisms that contribute to immune suppression in cancer. Their lead candidate, PhOx430, is designed to inhibit a specific glycosylation enzyme, thereby unmasking tumor cells to the immune system and reducing their invasiveness. This innovative approach aims to enhance the immune response against aggressive solid tumors, including challenging cases like Glioblastomas and Triple Negative Breast Cancers. PhOx430 has shown promising antitumoral efficacy in preclinical models and is optimized for oral administration, with plans for clinical trials already underway.

In addition to their primary focus on oncology, Phost'in Therapeutics is exploring the implications of N-glycosylation in various chronic and serious diseases. The company has a robust pipeline, with the capability to synthesize over 100 new compounds annually based on their proprietary scaffold. Their research is backed by a decade of academic collaboration and is supported by exclusive licenses on multiple patent families from prestigious institutions, including CNRS and the University of Montpellier. This foundation positions Phost'in as a significant player in the field of Glyco-Immuno-Oncology, with the potential to address a wide range of serious health conditions.

France

Phost’in Therapeutics discovers and develops First-In-Class Glycocalyx Modifiers for selective treatment of cancers and other serious diseases.  A new and innovative player in the field of Glyco-Immuno-Oncology, Phost’in Therapeutics develops a class of highly potent anti-cancer NCEs (new chemical entities) targeting a key glycosylation mechanism responsible for suppressing the immune response.  Our first generation of Glycosylation inhibitors aims to unblock immune response and down-modulate invasiveness for the treatment of aggressive solid tumors.

Phost'in Therapeutics

Company Details